Skip to content
[P]pubcas
Independent chemical reference Compare
Home/Chemicals/486-16-8
Chemical substance record

Carbinoxamine

486-16-8C16H19ClN2O290.794 g/mol
Organic/Inorganic Small MoleculeChEBI source record

An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease. — ChEBI

Safety references

Safety documents & references

Supplier matching matters

Find the safety document for your specific supplier, product number and grade.

Find a product-specific SDS

Search SDS PDFs Sigma-Aldrich Thermo Fisher

Safety guides and government classification records are not a manufacturer’s SDS. Match supplier, product number, concentration, physical form, region and revision before using a document.

Identity & molecular properties

Source-linked values
CAS number486-16-8ChEBI ↗
Molecular formulaC16H19ClN2OChEBI ↗
Molar mass290.794 g/molChEBI ↗
Monoisotopic mass290.11859 DaChEBI ↗
Formal charge0ChEBI ↗
ChEBI identifierCHEBI:3398ChEBI ↗

Cross-source molecular data

PubChem
Molar mass290.79 g/molPubChem ↗
Exact mass290.1185909 DaPubChem ↗
Computed XLogP2.9PubChem ↗
Topological polar surface area (Ų)25.4PubChem ↗
H-bond donors0PubChem ↗
H-bond acceptors3PubChem ↗
Rotatable bonds6PubChem ↗

PubChem computed values are shown separately from the ChEBI record. An exact InChIKey match was used to connect the records. Molecular descriptors do not describe a supplied product’s purity, particle size or performance.

Names & structural identifiers

Copy any identifier
carbinoxamine
2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-N,N-dimethylethanamine
OJFSXZCBGQGRNV-UHFFFAOYSA-N
CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1
InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3

Names & synonyms

2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-N,N-dimethylethanaminecarbinoxaminacarbinoxaminum

Names are supplied by ChEBI. Trade names and related synonyms may describe a broader product context.

Classification & relationships

ChEBI ontology
pyridinesChEBI parent class · 26421 ↗tertiary amino compoundChEBI parent class · 50996 ↗monochlorobenzenesChEBI parent class · 83403 ↗
organochlorine compoundorganic heterocyclic compoundorganic molecular entity

Roles recorded in ChEBI

H1-receptor antagonistantiparkinson drugmuscarinic antagonistanti-allergic agent

Database role annotations describe reported biological or chemical roles; they are not product approvals or recommendations for use.

Mass ↔ amount of substance

Calculated from sourced mass
Equivalent amount
0.00343886 mol

Uses 290.794 g/mol from ChEBI. Assumes the substance described by this record; no purity or concentration correction is applied.

Elemental composition

Theoretical mass fractions
C
Carbon · 16 atoms
66.09%
Cl
Chlorine · 1 atom
12.19%
N
Nitrogen · 2 atoms
9.63%
H
Hydrogen · 19 atoms
6.59%
O
Oxygen · 1 atom
5.50%

Calculated theoretical mass fractions from the reported formula and PubChem periodic-table atomic masses. These are not assay or purity results.

Research & patent references

Selected source associations
Functional group contributions to drug-receptor interactions. ↗Journal of medicinal chemistry · 1984 Dec · PMID 6094812
US2606195 · Patent reference ↗Patent cross-reference supplied by ChEBI. Association alone does not establish claim scope.
US2800485 · Patent reference ↗Patent cross-reference supplied by ChEBI. Association alone does not establish claim scope.
Search PubMed Google Scholar

Sources & record history

Checked 27 Sep 2026
EMBL-EBI ChEBI · CHEBI:3398

Release 255, 9 September 2026. ChEBI three-star (manually annotated) source entry. View original record ↗ · CC BY 4.0

NCBI PubChem · CID 2564 · retrieved 2026-09-27

PubCAS formats source data, connects references and computes explicitly labelled conversions. CAS cross-references are supplied by ChEBI; they do not constitute CAS verification or endorsement.

How this record was assembledSuggest a correction